These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 18784072)

  • 1. Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.
    Tripathi M; Nandana S; Yamashita H; Ganesan R; Kirchhofer D; Quaranta V
    J Biol Chem; 2008 Nov; 283(45):30576-84. PubMed ID: 18784072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.
    Tripathi M; Potdar AA; Yamashita H; Weidow B; Cummings PT; Kirchhofer D; Quaranta V
    Prostate; 2011 Feb; 71(2):184-96. PubMed ID: 20672321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.
    Li W; Wang BE; Moran P; Lipari T; Ganesan R; Corpuz R; Ludlam MJ; Gogineni A; Koeppen H; Bunting S; Gao WQ; Kirchhofer D
    Cancer Res; 2009 Nov; 69(21):8395-402. PubMed ID: 19843851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.
    Wittig-Blaich SM; Kacprzyk LA; Eismann T; Bewerunge-Hudler M; Kruse P; Winkler E; Strauss WS; Hibst R; Steiner R; Schrader M; Mertens D; Sültmann H; Wittig R
    Neoplasia; 2011 Jul; 13(7):579-89. PubMed ID: 21750652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration.
    Udayakumar TS; Chen ML; Bair EL; Von Bredow DC; Cress AE; Nagle RB; Bowden GT
    Cancer Res; 2003 May; 63(9):2292-9. PubMed ID: 12727852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepsin and prostate cancer.
    Wu Q; Parry G
    Front Biosci; 2007 Sep; 12():5052-9. PubMed ID: 17569629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteolytic activation of pro-macrophage-stimulating protein by hepsin.
    Ganesan R; Kolumam GA; Lin SJ; Xie MH; Santell L; Wu TD; Lazarus RA; Chaudhuri A; Kirchhofer D
    Mol Cancer Res; 2011 Sep; 9(9):1175-86. PubMed ID: 21875933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepsin promotes prostate cancer progression and metastasis.
    Klezovitch O; Chevillet J; Mirosevich J; Roberts RL; Matusik RJ; Vasioukhin V
    Cancer Cell; 2004 Aug; 6(2):185-95. PubMed ID: 15324701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of Hepsin and Underlying Signaling Pathways in Prostate Cancer.
    Lu L; Cole A; Huang D; Wang Q; Guo Z; Yang W; Lu J
    Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excess hepsin proteolytic activity limits oncogenic signaling and induces ER stress and autophagy in prostate cancer cells.
    Willbold R; Wirth K; Martini T; Sültmann H; Bolenz C; Wittig R
    Cell Death Dis; 2019 Aug; 10(8):601. PubMed ID: 31399560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
    Xuan JA; Schneider D; Toy P; Lin R; Newton A; Zhu Y; Finster S; Vogel D; Mintzer B; Dinter H; Light D; Parry R; Polokoff M; Whitlow M; Wu Q; Parry G
    Cancer Res; 2006 Apr; 66(7):3611-9. PubMed ID: 16585186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.
    Nandana S; Ellwood-Yen K; Sawyers C; Wills M; Weidow B; Case T; Vasioukhin V; Matusik R
    Prostate; 2010 May; 70(6):591-600. PubMed ID: 19938013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression profiling reveals hepsin overexpression in prostate cancer.
    Magee JA; Araki T; Patil S; Ehrig T; True L; Humphrey PA; Catalona WJ; Watson MA; Milbrandt J
    Cancer Res; 2001 Aug; 61(15):5692-6. PubMed ID: 11479199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent Hepsin overexpression and adenomatous polyposis coli deletion causes invasive prostate carcinoma in mice.
    Valkenburg KC; Hostetter G; Williams BO
    Prostate; 2015 Oct; 75(14):1579-85. PubMed ID: 26139199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
    Herter S; Piper DE; Aaron W; Gabriele T; Cutler G; Cao P; Bhatt AS; Choe Y; Craik CS; Walker N; Meininger D; Hoey T; Austin RJ
    Biochem J; 2005 Aug; 390(Pt 1):125-36. PubMed ID: 15839837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.
    Tang X; Mahajan SS; Nguyen LT; Béliveau F; Leduc R; Simon JA; Vasioukhin V
    Oncotarget; 2014 Mar; 5(5):1352-62. PubMed ID: 24657880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An allosteric anti-hepsin antibody derived from a constrained phage display library.
    Ganesan R; Zhang Y; Landgraf KE; Lin SJ; Moran P; Kirchhofer D
    Protein Eng Des Sel; 2012 Mar; 25(3):127-33. PubMed ID: 22258274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepsin inhibits CDK11p58 IRES activity by suppressing unr expression and eIF-2α phosphorylation in prostate cancer.
    Zhang C; Zhang M; Wu Q; Peng J; Ruan Y; Gu J
    Cell Signal; 2015 Apr; 27(4):789-97. PubMed ID: 25576733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy.
    Guo J; Li G; Tang J; Cao XB; Zhou QY; Fan ZJ; Zhu B; Pan XH
    Scand J Immunol; 2013 Sep; 78(3):248-57. PubMed ID: 23721092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane type 1 matrix metalloprotease cleaves laminin-10 and promotes prostate cancer cell migration.
    Bair EL; Chen ML; McDaniel K; Sekiguchi K; Cress AE; Nagle RB; Bowden GT
    Neoplasia; 2005 Apr; 7(4):380-9. PubMed ID: 15967115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.